Iqvia Holdings Inc (NYSE:IQV) Holdings Raised by World Asset Management Inc

World Asset Management Inc lifted its stake in shares of Iqvia Holdings Inc (NYSE:IQV) by 15.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,977 shares of the medical research company’s stock after purchasing an additional 1,584 shares during the quarter. World Asset Management Inc’s holdings in Iqvia were worth $1,789,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Iqvia by 2.0% during the second quarter. Vanguard Group Inc. now owns 18,316,909 shares of the medical research company’s stock valued at $2,947,191,000 after purchasing an additional 352,839 shares in the last quarter. BlackRock Inc. raised its stake in shares of Iqvia by 9.3% during the second quarter. BlackRock Inc. now owns 13,436,830 shares of the medical research company’s stock valued at $2,161,986,000 after purchasing an additional 1,146,138 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Iqvia by 19.3% during the second quarter. Janus Henderson Group PLC now owns 3,630,639 shares of the medical research company’s stock valued at $584,166,000 after purchasing an additional 588,179 shares in the last quarter. Farallon Capital Management LLC raised its stake in shares of Iqvia by 19.5% during the second quarter. Farallon Capital Management LLC now owns 2,579,011 shares of the medical research company’s stock valued at $414,963,000 after purchasing an additional 421,416 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its stake in shares of Iqvia by 18.5% during the second quarter. D. E. Shaw & Co. Inc. now owns 2,124,226 shares of the medical research company’s stock valued at $341,788,000 after purchasing an additional 331,390 shares in the last quarter. Institutional investors and hedge funds own 89.79% of the company’s stock.

Iqvia stock traded up $1.73 during midday trading on Thursday, hitting $145.21. The company’s stock had a trading volume of 651,818 shares, compared to its average volume of 1,191,201. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 1.72. The stock’s 50-day moving average price is $149.31 and its 200-day moving average price is $147.90. Iqvia Holdings Inc has a 12 month low of $104.90 and a 12 month high of $164.13. The company has a market capitalization of $27.99 billion, a PE ratio of 28.36, a price-to-earnings-growth ratio of 1.58 and a beta of 0.89.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.38 by $0.01. The firm had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.70 billion. Iqvia had a return on equity of 15.95% and a net margin of 2.31%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.29 EPS. As a group, equities analysts anticipate that Iqvia Holdings Inc will post 5.88 EPS for the current year.

A number of brokerages recently weighed in on IQV. Wells Fargo & Co lifted their price objective on shares of Iqvia from $170.00 to $178.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. SunTrust Banks boosted their price target on shares of Iqvia from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. ValuEngine cut shares of Iqvia from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. boosted their price target on shares of Iqvia from $160.00 to $180.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. Finally, Barclays set a $180.00 price target on shares of Iqvia and gave the stock a “buy” rating in a research report on Monday, July 15th. Four equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $166.46.

In other Iqvia news, insider Kevin C. Knightly sold 6,945 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $158.53, for a total transaction of $1,100,990.85. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Group Holdings (Sbs) Advis Tpg sold 2,616,028 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $156.85, for a total value of $410,323,991.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,627,251 shares of company stock worth $412,103,046. Corporate insiders own 6.00% of the company’s stock.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More: Tariff

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.